FDA approval for the transcatheter aortic valve replacement therapy, the SAPIEN 3 platform, for severe aortic stenosis patients without symptoms – Edwards Life Sciences
Edwards Lifesciences announced that the(FDA has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the… read more.



